NCT01451918View on ClinicalTrials.gov

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
DyslipidaemiaInsulin Resistance
Interventions
DRUG

Resveratrol

500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.

Trial Locations (1)

Unknown

Toronto General Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University Health Network, Toronto

OTHER

NCT01451918 - Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol | Biotech Hunter | Biotech Hunter